Bluejay Diagnostics, Inc. (BJDX) vs Jupiter Neurosciences, Inc. (JUNS)

A side-by-side comparison of Bluejay Diagnostics, Inc. and Jupiter Neurosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BJDX vs JUNS

growth of $100 · dividends reinvested · last 2y
BJDX -94.6% (-76.8%/yr)JUNS -99.4% (-92.3%/yr)BJDX compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $10020252026$5$1
BJDX JUNS

BJDX vs JUNS: by the numbers

  • •JUNS is the larger company ($1M vs $854260 market cap).
  • •Both run net losses; BJDX's is the smaller (0.00% vs -14220.12% net margin).

Metrics side by side

Valuation

MetricBJDXJUNS
P/S ratioN/A20.53
P/B ratio0.09N/A

Profitability

MetricBJDXJUNS
Gross margin0.00%88.34%
Operating margin0.00%-40873.19%
Net margin0.00%-14220.12%
ROE-77.23%N/A
ROIC-77.55%-709.40%

Growth (annualized)

MetricBJDXJUNS
Revenue CAGR (5Y)N/A-47.77%

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.